Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Prepaid Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Prepaid Assets for 11 consecutive years, with $68.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 129.15% to $68.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $68.4 million, a 129.15% increase, with the full-year FY2025 number at $68.4 million, up 129.15% from a year prior.
  • Prepaid Assets was $68.4 million for Q4 2025 at Intellia Therapeutics, up from $59.8 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $68.4 million in Q4 2025 to a low of $14.0 million in Q3 2021.
  • A 5-year average of $32.7 million and a median of $26.5 million in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: surged 222.72% in 2021, then plummeted 53.65% in 2025.
  • Intellia Therapeutics' Prepaid Assets stood at $18.6 million in 2021, then rose by 9.81% to $20.4 million in 2022, then surged by 143.3% to $49.7 million in 2023, then plummeted by 39.92% to $29.8 million in 2024, then soared by 129.15% to $68.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Prepaid Assets are $68.4 million (Q4 2025), $59.8 million (Q3 2025), and $24.9 million (Q2 2025).